Details for New Drug Application (NDA): 203824
NDA 203824 describes AMOXICILLIN AND CLAVULANATE POTASSIUM, which is a drug marketed by Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Deva Holding As, Hikma Pharms, Micro Labs, Micro Labs Ltd India, Sandoz, Sandoz Inc, Sun Pharm Inds Ltd, Apotex Inc, and Regcon Holdings, and is included in forty-one NDAs. It is available from thirty-one suppliers. Additional details are available on the AMOXICILLIN AND CLAVULANATE POTASSIUM profile page.
The generic ingredient in AMOXICILLIN AND CLAVULANATE POTASSIUM is amoxicillin; clavulanate potassium. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the amoxicillin; clavulanate potassium profile page.
The generic ingredient in AMOXICILLIN AND CLAVULANATE POTASSIUM is amoxicillin; clavulanate potassium. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the amoxicillin; clavulanate potassium profile page.
Summary for 203824
| Tradename: | AMOXICILLIN AND CLAVULANATE POTASSIUM |
| Applicant: | Hikma Pharms |
| Ingredient: | amoxicillin; clavulanate potassium |
| Patents: | 0 |
Pharmacology for NDA: 203824
| Mechanism of Action | beta Lactamase Inhibitors |
Suppliers and Packaging for NDA: 203824
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AMOXICILLIN AND CLAVULANATE POTASSIUM | amoxicillin; clavulanate potassium | TABLET;ORAL | 203824 | ANDA | Hikma Pharmaceuticals USA Inc. | 0143-9249 | 0143-9249-20 | 20 TABLET in 1 BOTTLE (0143-9249-20) |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | amoxicillin; clavulanate potassium | TABLET;ORAL | 203824 | ANDA | A-S Medication Solutions | 50090-3179 | 50090-3179-0 | 20 TABLET in 1 BOTTLE (50090-3179-0) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 875MG;EQ 125MG BASE | ||||
| Approval Date: | Aug 23, 2016 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
